RCUSArcus Biosciences, Inc.

1. Aug 5, 2026Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update.Earnings release · press release
2. May 5, 2026Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update.Earnings release · press release
3. Apr 20, 2026STAR-121 Update. On April 20, 2026, Arcus Biosciences, Inc. (the “Company”) announced the discontinuation of the Phase 3 STAR-121 study, which is being conducted in collaboration with Gilead Sciences, Inc. (“Gilead”), due to futility.Other event · Form 8-K
4. Mar 23, 2026On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. (the “Company”) of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026.Director or officer change · Form 8-K
5. Feb 25, 2026Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update.Earnings release · press release
6. Dec 18, 2025On December 18, 2025 (the “Closing Date”), Arcus Biosciences, Inc. (the “Company”) entered into a First Amendment to the Loan and Security Agreement (the “First Amendment”) with the several banks and other financial institutions or entities party thereto (the “Lenders”), as lenders, and Hercules Capital, Inc. …Material agreement entered · Form 8-K
7. Dec 12, 2025On December 12, 2025, Arcus Biosciences, Inc. (the “Company”) announced the discontinuation of the Phase 3 STAR-221 study due to futility.Other event · Form 8-K
8. Nov 3, 2025On October 30, 2025, Arcus Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the public offering …Other event · Form 8-K
9. Oct 28, 2025Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update.Earnings release · press release
10. Oct 14, 2025On October 12, 2025, Arcus Biosciences, Inc. (the “Company”) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.Other event · Form 8-K
11. Oct 6, 2025ARC-20 Updates On October 6, 2025, Arcus Biosciences, Inc. (the “Company”) presented updated data from the monotherapy cohorts of ARC-20, a Phase 1/1b study evaluating different doses and combinations with casdatifan, and shared new research programs in immunology and inflammation.Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.